con il contributo non condizionante di:
SESSION I - THE EVOLVING ROLE OF CHECKPOINT INHIBITORS IN LYMPHOMAS
Chairmen: S.M. Ansell, P.L. Zinzani
In first line Hodgkin lymphoma
A.F. HerreraNovel checkpoint inhibitors
G. CollinsHow to overcome resistance to checkpoints
S.M. AnsellSESSION II - BISPECIFIC T-CELL ENGAGERS IN LYMPHOMA AND MYELOMA
Chairmen: A.D. Cohen, F. Gay
Overview aggressive NHL
C. Carlo-StellaResistance and combinations of bispecifics
H. EinseleSESSION III - LYMPHOMA: CLINICAL UPDATES IN CAR-T THERAPIES
Chairmen: P. Corradini, S.J. Schuster
First line CAR-T: ZUMA 12 and beyond
S.S. NeelapuCAR-T for follicular lymphoma and real-world data
S.J. SchusterCAR-T for mantle cell lymphoma
G.I. IacoboniCAR-T for T-cell lymphomas
C.A. RamosSESSION IV - CAR-T RESISTANCE AND NEXT-GENERATION CAR-T THERAPIES FOR NHL
Chairmen: M. Jain, C. Quintarelli
Mechanisms of resistance: clinical evidence
S.J. SchusterThe role of lymphodepletion
G. GhilardiCAR-T and microbiome
R. JenqOvercoming CAR-T toxicities
S. KenderianSESSION VI - NOVEL IMMUNOTHERAPIES FOR LYMPHOID MALIGNANCIES
Chairmen: S.S. Neelapu, M. Ruella
Allo CAR-T cells
S.S. NeelapuGamma delta CAR-T20 cells
S.S. NeelapuSESSION VII - CAR-T CELL IMMUNOTHERAPY FOR MULTIPLE MYELOMA
Chairmen: M. Cavo, M.V. Mateos
Clinical results in late lines
A.D. CohenClinical results in early lines
M.V. Mateosovel CAR-T and combination
A.D. CohenSESSION VIII - HOT DEBATES IN IMMUNOTHERAPY FOR LYMPHOMAS
Chairmen: M. Ruella, P.L. Zinzani